| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Gia Han Le, Sabrina Wong, Sebastian Badulescu, Hezekiah Au, Joshua D Di Vincenzo, Hartej Gill, Lee Phan, Taeho Greg Rhee, Roger Ho, Kayla M Teopiz, Angela T H Kwan, Joshua D Rosenblat, Rodrigo B Mansur, Roger S McIntyr. Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review. Journal of affective disorders. 2024-04-03. PMID:38570038. |
spectral signatures of psilocybin, lysergic acid diethylamide (lsd) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: a systematic review. |
2024-04-03 |
2024-04-06 |
human |
| Hanna Molla, Royce Lee, Ilaria Tare, Harriet de Wi. Greater subjective effects of a low dose of LSD in participants with depressed mood. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2023-12-02. PMID:38042914. |
the high bdi group also reported a greater decline in bdi depression scores 48-h after lsd, compared to placebo. |
2023-12-02 |
2023-12-10 |
human |
| Emily Harri. LSD Use Increasing More Among People With Depression. JAMA. 2023-10-25. PMID:37878343. |
lsd use increasing more among people with depression. |
2023-10-25 |
2023-11-08 |
Not clear |
| Claire A Walsh, Lauren Gorfinkel, Dvora Shmulewitz, Malki Stohl, Deborah S Hasi. Use of Lysergic Acid Diethylamide by Major Depression Status. JAMA psychiatry. 2023-10-11. PMID:37819655. |
renewed interest in the clinical potential of hallucinogens may lead people with depression to a generally more positive view of the use of lysergic acid diethylamide (lsd). |
2023-10-11 |
2023-10-15 |
Not clear |
| Claire A Walsh, Lauren Gorfinkel, Dvora Shmulewitz, Malki Stohl, Deborah S Hasi. Use of Lysergic Acid Diethylamide by Major Depression Status. JAMA psychiatry. 2023-10-11. PMID:37819655. |
therefore, past-year lsd use among people with depression may be increasing in prevalence. |
2023-10-11 |
2023-10-15 |
Not clear |
| Carina Joy Donegan, Dimitri Daldegan-Bueno, Rachael Sumner, David Menkes, William Evans, Nicholas Hoeh, Frederick Sundram, Lisa Reynolds, Rhys Ponton, Alana Cavadino, Todd Smith, Partha Roop, Nathan Allen, Binu Abeysinghe, Darren Svirskis, Anna Forsyth, Mahima Bansal, Suresh Muthukumaraswam. An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1). Pilot and feasibility studies. vol 9. issue 1. 2023-10-05. PMID:37798662. |
in light of problems with the tolerability and efficacy of available treatments [2], a global trend is emerging for patients to self-treat depression with microdoses of psychedelic drugs such as lysergic acid diethylamide (lsd) and psilocybin [3]. |
2023-10-05 |
2023-10-07 |
human |
| Natália Bernardi Videira, Vijayalekshmi Nair, Valérie Paquet, Dean Calhou. The changing outlook of psychedelic drugs: The importance of risk assessment and occupational exposure limits. Journal of applied toxicology : JAT. 2023-08-30. PMID:37646119. |
serotonergic psychedelics, such as lysergic acid diethylamide (lsd), psilocybin, dimethyltryptamine (dmt), and 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt), are currently being investigated for the treatment of psychiatric disorders such as depression and anxiety. |
2023-08-30 |
2023-09-07 |
Not clear |
| Natalie A Boychuk, Niamh S Mulrooney, Nicole R Kelly, Aaron J Goldenberg, Ellen J Silver, Melissa P Wasserstei. Parental Depression and Anxiety Associated with Newborn Bloodspot Screening for Rare and Variable-Onset Disorders. International journal of neonatal screening. vol 8. issue 4. 2022-11-22. PMID:36412585. |
parents of children with an lsd or x-ald diagnosis clinically may have higher odds of depression (or: 6.06, 95% ci: 1.64-24.96) compared to parents of children with the same disorders identified through nbs, controlling for covariates. |
2022-11-22 |
2023-08-14 |
human |
| Agnieszka D Sekula, Luke Downey, Prashanth Puspanatha. Virtual Reality as a Moderator of Psychedelic-Assisted Psychotherapy. Frontiers in psychology. vol 13. 2022-03-21. PMID:35310225. |
psychotherapy with the use of psychedelic substances, including psilocybin, lysergic acid diethylamide (lsd), ketamine, and 3,4-methylenedioxymethamphetamine (mdma), has demonstrated promise in treatment of post-traumatic stress disorder (ptsd), anxiety, addiction, and treatment-resistant depression. |
2022-03-21 |
2023-08-13 |
human |
| Lersi D Durán, Ana Margarida Almeida, Ana Cristina Lopes, Margarida Figueiredo-Brag. Impact of a Digital Intervention for Literacy in Depression among Portuguese University Students: A Randomized Controlled Trial. Healthcare (Basel, Switzerland). vol 10. issue 1. 2022-01-21. PMID:35052329. |
using the scheffé and least significant difference (lsd) multiple comparisons test, it was found that g1, which received the deep audiovisual intervention, differed significantly from the other groups, with higher depression knowledge scores in post-intervention stages. |
2022-01-21 |
2023-08-13 |
human |
| Lea J Mertens, Katrin H Prelle. Classical Psychedelics as Therapeutics in Psychiatry - Current Clinical Evidence and Potential Therapeutic Mechanisms in Substance Use and Mood Disorders. Pharmacopsychiatry. vol 54. issue 4. 2021-10-28. PMID:33472250. |
modern clinical research is currently gaining momentum and provides new evidence for the safety and efficacy of classical psychedelics (primarily psilocybin, but also lsd and ayahuasca) in the treatment of different psychiatric conditions, including substance use and mood disorders.in this review article, we outline common pathological mechanisms of substance use disorders (sud) and unipolar depression. |
2021-10-28 |
2023-08-13 |
human |
| Yunxi Gao, Anthony Callana. Influence of surface topography on PCL electrospun scaffolds for liver tissue engineering. Journal of materials chemistry. B. vol 9. issue 38. 2021-10-26. PMID:34491259. |
scaffolds with large surface depression (2 μm) (lsd), small surface depression (0.37 μm) (ssd), and no surface depression (nsd) were fabricated by using a solvent-nonsolvent system. |
2021-10-26 |
2023-08-13 |
Not clear |
| Wayne Hal. Why was early therapeutic research on psychedelic drugs abandoned? Psychological medicine. 2021-10-21. PMID:34670633. |
advocates of the therapeutic use of psychedelic drugs have argued that a promising approach to treatment was prematurely abandoned in the 1960s primarily because of richard nixon's 'war on drugs'.this paper (1) briefly describes research in the 1950s and 1960s in north america on the use of lsd to treat alcohol dependence, anxiety in terminal illness, and anxiety and depression; and (2) discusses the factors that led to its abandonment. |
2021-10-21 |
2023-08-13 |
Not clear |
| Dominika Psiuk, Emilia Nowak, Krystian Cholewa, Urszula Łopuszańska, Marzena Samardakiewic. The Potential Role of Serotonergic Hallucinogens in Depression Treatment. Life (Basel, Switzerland). vol 11. issue 8. 2021-08-31. PMID:34440508. |
a literature search of the pubmed/medline database identified 14 clinical trials from the last 10 years that examined the use of psilocybin, mdma, dmt, or lsd for the treatment of depression symptoms. |
2021-08-31 |
2023-08-13 |
Not clear |
| Gniewko Więckiewicz, Iga Stokłosa, Magdalena Piegza, Piotr Gorczyca, Robert Pudl. Lysergic Acid Diethylamide, Psilocybin and Dimethyltryptamine in Depression Treatment: A Systematic Review. Pharmaceuticals (Basel, Switzerland). vol 14. issue 8. 2021-08-31. PMID:34451890. |
the aim of this study was to evaluate the efficiency of lsd, psilocybin and dmt in depression treatment in the light of current medical literature. |
2021-08-31 |
2023-08-13 |
Not clear |
| Meghan Hibicke, Alexus N Landry, Hannah M Kramer, Zoe K Talman, Charles D Nichol. Psychedelics, but Not Ketamine, Produce Persistent Antidepressant-like Effects in a Rodent Experimental System for the Study of Depression. ACS chemical neuroscience. vol 11. issue 6. 2021-05-24. PMID:32133835. |
to address these questions, we tested psilocybin, lysergic acid diethylamide (lsd), and ketamine in a rat model for depression. |
2021-05-24 |
2023-08-13 |
human |
| Felix Müller, Markus Mühlhauser, Friederike Holze, Undine E Lang, Marc Walter, Matthias E Liechti, Stefan Borgward. Treatment of a Complex Personality Disorder Using Repeated Doses of LSD-A Case Report on Significant Improvements in the Absence of Acute Drug Effects. Frontiers in psychiatry. vol 11. 2020-11-17. PMID:33192701. |
a 39-year-old female patient suffering from severe, treatment-resistant depression and other symptoms associated with a complex personality disorder was admitted to our open psychiatric ward for an experimental treatment with lysergic acid diethylamide (lsd). |
2020-11-17 |
2023-08-13 |
Not clear |
| Nadia Ali, Scott Gillespie, Dawn Lane. Treatment of Depression in Adults with Fabry Disease. JIMD reports. vol 38. 2020-10-01. PMID:28417336. |
in conclusion, the present pilot study supports the efficacy of psychological treatment for depression in people with fd, highlighting the importance of having health psychologists housed in lsd treatment centers, rather than specialty psychology/psychiatry settings, to increase participation and decrease potential obstacles to access due to perceived stigma. |
2020-10-01 |
2023-08-13 |
human |
| Shawn Y Forrester, Nusrat Jaha. Depression Onset in Long-term Adolescent Cannabinoid Use: A Neurobiological Review. Cureus. vol 12. issue 4. 2020-09-28. PMID:32455076. |
data were included from studies that satisfied the following criteria: (i) published within the last 10 years (older studies were included based on relevance), (ii) on adolescent subjects (animal or human), (iii) published in english, (iv) journal articles, systematic reviews, meta-analyses, clinical trials, observational studies (animal or human), (v) on subjects who had unipolar depression with no comorbidities, and (vi) on subjects who used cannabis [with no confounding variables such as the use of ethanol, nicotine, cocaine, lysergic acid diethylamide (lsd), and heroin; and no medical conditions such as comorbid psychosis, mania, or autism]. |
2020-09-28 |
2023-08-13 |
human |
| Rémi Corne, Raymond Mongea. [Neurotrophic mechanisms of psychedelic therapy]. Biologie aujourd'hui. vol 213. issue 3-4. 2020-05-18. PMID:31829932. |
serotonergic psychedelics such as psilocybin and lysergic acid diethylamide (lsd) are gaining attention as potential treatments for depression and addiction, similarly to 3,4-methylenedioxymethamphetamine (mdma) for post-traumatic stress disorder (ptsd), and ibogaine for addiction. |
2020-05-18 |
2023-08-13 |
Not clear |